Literature DB >> 16423991

The single nucleotide polymorphism IVS1+309 in mouse double minute 2 does not affect risk of familial breast cancer.

Stefan Wilkening1, Justo Lorenzo Bermejo, Barbara Burwinkel, Rüdiger Klaes, Claus R Bartram, Alfons Meindl, Peter Bugert, Rita K Schmutzler, Barbara Wappenschmidt, Michael Untch, Kari Hemminki, Asta Försti.   

Abstract

The mouse double minute 2 (MDM2) oncoprotein promotes cell survival and cell cycle progression by inhibiting the p53 tumor suppressor protein. Further, MDM2 overexpression can inhibit DNA double-strand break repair in a p53-independent manner. Recently, it was shown that a single nucleotide polymorphism (SNP) in the MDM2 promoter was associated with an accelerated tumor formation in individuals with a p53 mutation. The present case-control study investigated the association of this SNP (IVS1+309) with the risk and the age of onset of familial breast cancer in patients with unknown p53 mutation status. Data from 549 women affected by familial breast cancer and 1,065 healthy controls were analyzed. The cases did not carry BRCA1/2 mutations. Cases and controls showed a similar genotype distribution and the SNP did not seem to modify the age of onset of familial breast cancer. The data were also examined taking into account the presence of any additional cancer after breast cancer and the family history of cases; however, no association was found. These results suggest that the SNP IVS1+309 alone affects neither the risk nor the age of onset of heritable breast cancer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16423991     DOI: 10.1158/0008-5472.CAN-05-3168

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  11 in total

1.  Individual and combined effects of MDM2 SNP309 and TP53 Arg72Pro on breast cancer risk: an updated meta-analysis.

Authors:  Hongtao Cheng; Biao Ma; Ran Jiang; Wei Wang; Hui Guo; Na Shen; Dapeng Li; Qunzi Zhao; Rui Wang; Pengfei Yi; Yue Zhao; Zeming Liu; Tao Huang
Journal:  Mol Biol Rep       Date:  2012-06-24       Impact factor: 2.316

2.  MDM2 SNP309 polymorphism and breast cancer risk: a meta-analysis.

Authors:  Erjiang Zhao; Dan Cui; Ling Yuan; Weiquan Lu
Journal:  Mol Biol Rep       Date:  2011-07-03       Impact factor: 2.316

3.  No association of MDM2 SNP309 with risk of glioblastoma and prognosis.

Authors:  Soufiane El Hallani; Yannick Marie; Ahmed Idbaih; Mathieu Rodero; Blandine Boisselier; Florence Laigle-Donadey; François Ducray; Jean-Yves Delattre; Marc Sanson
Journal:  J Neurooncol       Date:  2007-06-14       Impact factor: 4.130

4.  Clinical significance of TP53 (R72P) and MDM2 (T309G) polymorphisms in breast cancer patients.

Authors:  P Yadav; M Masroor; K Tanwer; R Mir; J Javid; I Ahmad; M Zuberi; R C M Kaza; S K Jain; N Khurana; P C Ray; A Saxena
Journal:  Clin Transl Oncol       Date:  2015-11-09       Impact factor: 3.405

5.  MDM2 SNP309, gene-gene interaction, and tumor susceptibility: an updated meta-analysis.

Authors:  Yan Wan; Wei Wu; Zhihua Yin; Peng Guan; Baosen Zhou
Journal:  BMC Cancer       Date:  2011-05-29       Impact factor: 4.430

6.  Association between MDM2 rs 2279744 polymorphism and breast cancer susceptibility: a meta-analysis based on 9,788 cases and 11,195 controls.

Authors:  Jie Gao; An-Jing Kang; Shuai Lin; Zhi-Jun Dai; Shu-Qun Zhang; Di Liu; Yang Zhao; Peng-Tao Yang; Meng Wang; Xi-Jing Wang
Journal:  Ther Clin Risk Manag       Date:  2014-04-15       Impact factor: 2.423

7.  Effects of the single nucleotide polymorphism at MDM2 309 on breast cancer patients with/without BRCA1/2 mutations.

Authors:  Hovav Nechushtan; Tamar Hamburger; Susan Mendelson; Luna Kadouri; Nir Sharon; Eli Pikarsky; Tamar Peretz
Journal:  BMC Cancer       Date:  2009-02-18       Impact factor: 4.430

8.  Results based on 124 cases of breast cancer and 97 controls from Taiwan suggest that the single nucleotide polymorphism (SNP309) in the MDM2 gene promoter is associated with earlier onset and increased risk of breast cancer.

Authors:  Ying-Fang Sun; Jyh-Der Leu; Su-Mei Chen; I-Feng Lin; Yi-Jang Lee
Journal:  BMC Cancer       Date:  2009-01-13       Impact factor: 4.430

9.  MDM2 SNP309 is associated with high grade node positive breast tumours and is in linkage disequilibrium with a novel MDM2 intron 1 polymorphism.

Authors:  Fiona E M Paulin; Mary O'Neill; Gillian McGregor; Andrew Cassidy; Alison Ashfield; Clinton W Ali; Alastair J Munro; Lee Baker; Colin A Purdie; David P Lane; Alastair M Thompson
Journal:  BMC Cancer       Date:  2008-10-01       Impact factor: 4.430

10.  Association of TP53 codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patients.

Authors:  Tatsuya Toyama; Zhenhuan Zhang; Mariko Nishio; Maho Hamaguchi; Naoto Kondo; Hirotaka Iwase; Hiroji Iwata; Satoru Takahashi; Hiroko Yamashita; Yoshitaka Fujii
Journal:  Breast Cancer Res       Date:  2007       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.